E
Eugene Rosenthal
Researcher at National Institutes of Health
Publications - 13
Citations - 1521
Eugene Rosenthal is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Cystic fibrosis transmembrane conductance regulator & Genetic enhancement. The author has an hindex of 10, co-authored 13 publications receiving 1505 citations.
Papers
More filters
Journal ArticleDOI
In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium
Melissa A. Rosenfeld,Kunihiko Yoshimura,Bruce C. Trapnell,Koichi Yoneyama,Eugene Rosenthal,Wilfried Dalemans,Masashi Fukayama,Joachim Bargon,L Stier,Leslie Stratford-Perricaudet,Michel Perricaudet,William B. Guggino,Andrea Pavirani,J P Lecocq,Ronald G. Crystal +14 more
TL;DR: Observations suggest the feasibility of in vivo CFTR gene transfer as therapy for the pulmonary manifestations of CF.
Journal ArticleDOI
Genome editing technologies: defining a path to clinic.
Jacqueline Corrigan-Curay,Marina O'Reilly,Donald B. Kohn,Paula M. Cannon,Gang Bao,Frederic D. Bushman,Dana Carroll,Toni Cathomen,J. Keith Joung,David Roth,Michel Sadelain,Andrew M. Scharenberg,Christof von Kalle,Feng Zhang,Robert Jambou,Eugene Rosenthal,Morad Hassani,Aparna Singh,Matthew H. Porteus +18 more
TL;DR: Recently developed genomic editing technologies have the potential to be powerful tools for gene therapy because of their ability to inactivate genes, correct mutated sequences, or insert intact genes While the genomic editing field is advancing at an exceptionally rapid pace, there remain key issues regarding development of appropriate preclinical assays to evaluate off-target effects and establish safety.
Journal ArticleDOI
Recombinant, replication-defective adenovirus gene transfer vectors induce cell cycle dysregulation and inappropriate expression of cyclin proteins.
TL;DR: First-generation adenovirus vectors that had been rendered replication defective by removal of the E1 region of the viral genome or lacking the Ad E3 region in addition to E1 sequences induced G2 cell cycle arrest and inhibited traverse across G1/S in primary and immortalized human bronchial epithelial cells.
Journal ArticleDOI
T-cell immunotherapy: looking forward.
Jacqueline Corrigan-Curay,Hans-Peter Kiem,David Baltimore,Marina O'Reilly,Renier J. Brentjens,Laurence J.N. Cooper,Stephen J. Forman,Stephen Gottschalk,Philip D. Greenberg,Richard P. Junghans,Helen E. Heslop,Michael C. Jensen,Crystal L. Mackall,Carl H. June,Oliver W. Press,Daniel J. Powell,Antoni Ribas,Steven A. Rosenberg,Michel Sadelain,Brian G. Till,Amy P. Patterson,Robert Jambou,Eugene Rosenthal,Linda Gargiulo,Maureen Montgomery,Donald B. Kohn +25 more
TL;DR: The T Cell Immunotherapy: Optimizing T-cell trial design workshop as discussed by the authors was a workshop sponsored by the National Institutes of Health's Office of Biotechnology Activities (OBA), which brought together researchers to discuss the scientific advances and share new data on key trial design issues.
Journal ArticleDOI
Challenges in vector and trial design using retroviral vectors for long-term gene correction in hematopoietic stem cell gene therapy.
Jacqueline Corrigan-Curay,Odile Cohen-Haguenauer,Odile Cohen-Haguenauer,Marina O'Reilly,Susan R. Ross,Hung Fan,Naomi Rosenberg,Nikunj V. Somia,Nancy M. P. King,Theodore Friedmann,Cynthia E. Dunbar,Alessandro Aiuti,Luigi Naldini,Christopher Baum,Christof von Kalle,Hans-Peter Kiem,Eugenio Montini,Frederic D. Bushman,Brian P. Sorrentino,Manuel J.T. Carrondo,Harry L. Malech,Gösta Gahrton,Robyn S. Shapiro,Linda Wolff,Eugene Rosenthal,Robert Jambou,John A. Zaia,Donald B. Kohn +27 more
TL;DR: Recent reports of insertional mutagenesis leading to myelodysplastic syndrome in a trial for chronic granulomatous disease and a case of leukemia in a Trial for Wiskott-Aldrich syndrome, both of which used g-retroviral vectors, underscored that this type of toxicity can also apply to other disease settings.